Overcoming crizotinib resistance in ALK-rearranged non-small cell lung cancer

Lung Cancer. 2014 Aug;85(2):335-6. doi: 10.1016/j.lungcan.2014.04.013. Epub 2014 May 5.

Authors

Xiaolong Qi¹, Wang Ma², Sen Li³, Caicun Zhou⁴

Affiliations

¹ Tongji University School of Medicine, Shanghai 200092, China.
² Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
³ Department of Spine Surgery, the Affiliated Hospital of Luzhou Medical College, Luzhou 646000, China.
⁴ Department of Oncology, Shanghai Pulmonary Hospital, Shanghai 200433, China. Electronic address: caicunzhoudr@163.com.

PMID: 24854402
DOI: 10.1016/j.lungcan.2014.04.013

No abstract available

Publication types

Letter
Comment

MeSH terms

Antineoplastic Agents / pharmacology*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Drug Resistance, Neoplasm / genetics*
Humans
Lung Neoplasms / drug therapy*
Pyrazoles / pharmacology*
Pyridines / pharmacology*
Translocation, Genetic*

Substances

Antineoplastic Agents
Pyrazoles
Pyridines